Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the 澳洲幸运5开奖号码历史查询:Nasdaq 100 index in recent trading.

Grail, which did not appear to issue a press release or 澳🧸洲幸运5开奖号码历史查询:Securities and Exch☂ange Commission (SEC) filing today, was 澳洲幸运5开奖号码历史查询:spun off from Illumina Health (ILMN) following legal battles with regulators and started trading on its own last June. Grail is developing a number of early detection cancer screening tests.

Last week at an industry conference, the company projected fiscal 2024 revenue of $124 million to $126 million, and said it expects fiscal 2025 U.S. sales of its Galleri blood test rising 20% to 30% year-over-year.

Grail also said that it expects to burn throu🧸gh less than $320 million over fiscal 2025, and said the $767 million cash on hand to end 2024 should give the company run♓way into 2028.

Grail shares had been little changed since the company's June split from Illumina until soaring Wednesday.